3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
115
Brain Neoplasms
114
Prostatic Neoplasms
101
Neoplasm Metastasis
79
Carcinoma, Hepatocellular
69
Lung Neoplasms
67
Pancreatic Neoplasms
64
Breast Neoplasms
48
Melanoma
37
Carcinoma, Renal Cell
33
Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
21
Colorectal Neoplasms
20
Liver Neoplasms
19
Glioblastoma
18
Small Cell Lung Carcinoma
14
Head and Neck Neoplasms
14
Sarcoma
11
Kidney Neoplasms
11
Glioma
10
Recurrence
8
Urinary Bladder Neoplasms
7
Radiation Injuries
6
Neuroma, Acoustic
6
Cholangiocarcinoma
6
Adenocarcinoma
6
Uveal Melanoma
5
Uterine Cervical Neoplasms
5
Prostate Cancer Metastatic
5
Ovarian Neoplasms
5
Interventions
Ipilimumab
6
tremelimumab
5
durvalumab
5
Nivolumab
3
Capecitabine
3
Radiotherapy
2
Radiation
2
Paclitaxel
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
relatlimab
1
poly ICLC
1
lenvatinib
1
folfirinox
1
balstilimab
1
Vaccines
1
Vaccination
1
Surgical Procedures, Operative
1
Radiosurgery
1
Platinum
1
Peptides
1
Pemetrexed
1
Oxaliplatin
1
Opdualag
1
Monophenol Monooxygenase
1
Melphalan
1
Leucovorin
1
Immunotherapy
1
Fluorouracil
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Radiosurgery
×
Clear all
NCT05915481
2023-06-23
SCARCE
Peking University Third Hospital
Phase 1/2
Unknown
60 enrolled